10 Stocks to Shake the Market

Recs

11

Motley Fool Stock Advisor

Since 2002, David and Tom Gardner have returned 28.89% while the S&P 500 returned -11.53%. Try Stock Advisor free for 30 days.

Stock Advisor

In music, they're called “one-hit wonders” -- singers who belt out tune after tune, but are never able to regain the magic of their big hit song. Think Norman Greenbaum's "Spirit in the Sky" or Brownsville Station's "Smokin' in the Boys Room" -- monster hits never to be repeated.

We have seen similar one-hit wonders in stocks, too, like Pets.com or drkoop.com. These are companies that burst onto the scene -- many during the tech-bubble heyday -- but never lived up to the promise they held.

Whole lotta shakin' going on
While nostalgia's fun, "10 Stocks to Shake the Market" isn't about finding stocks that can't repeat their success. Instead, it's about looking at those that have made big moves and are likely to continue doing so.

To that end, we're looking at 10 stocks that made some of the biggest upward moves over the past month. We'll then pair this info with the ratings issued by our Motley Fool CAPS community. Higher ratings suggest that members believe a stock will continue to move higher in the future and outperform the market.

In the 20 months since we first began tracking the collective intelligence at CAPS, the data shows that newly minted five-star stocks offer the best opportunities for investors, while the lowest-rated companies have fared the worst. Four-star stocks outperformed the market by seven percentage points, and five-star stocks -- those with top honors in CAPS -- did even better.

Stock

30-Day % Change

CAPS Rating (out of 5)

StemCells (Nasdaq: STEM)

193.49%

**

Cheniere Energy (AMEX: LNG)

125.00%

**

UAL (Nasdaq: UAUA)

121.59%

*

AirTran Holdings

88.27%

**

PetroHawk Energy (NYSE: HK)

87.66%

****

Northern Dynasty Minerals

73.89%

****

Geron (Nasdaq: GERN)

71.15%

***

Nektar Therapeutics (Nasdaq: NKTR)

67.70%

**

Southwestern Energy (NYSE: SWN)

67.56%

***

Archer Daniels Midland (NYSE: ADM)

52.56%

****

Not bad -- half of these stocks carry ratings of three stars or better. Let’s zero in on some that CAPS members think will continue to outperform the market.

Geron
The potential for stem-cell companies was unleashed with the election of Barack Obama, who has indicated that he supports federal funding for embryonic stem-cell research. That fueled interest not only in Geron, but in StemCells and Celgene as well. CAPS member blary54 finds Geron to be a financially fit competitor in the space, a fact that should power it forward:

big stem cell player. I like this stock with Obama being president.

This company has no debt and I see the stock exploding in the next couple years.

StemCells
But top-rated CAPS All-Star mpapile says "not so fast," arguing that if you look past the headlines, you'll see that players like StemCells aren't going to be any better off, Obama or not:

Lets look at the facts here, this company makes no money, and is NOT going to be directly affected by the political change! If you know anything about research and stem cells the only restriction on stem cells was that embryonic stem cells were not allowed to be used in federally funded research. This did not mean that private companies were not allowed to use embryonic stem cells.

So here is a company that specializes in tissue derived stem cells supposedly, and has been around for 15 years and is not even profitable. If anything, there is going to be more public research using embryonic lines now which will not help StemCells. In fact, it means govt finances will be used to move ahead in university labs, not in their labs.

You can read all of mpapile's analysis of the situation on StemCells' CAPS page.

United Airlines
Shares of United Airlines have doubled in recent weeks as oil prices continue their slide, and the cost-cutting measures implemented earlier this year can only help matters more. Yet though capacity has been cut, traffic is down as well, and the credit crisis may yet envelop the industry. CAPS All-Star POSstocks acknowledges that the short term may not be favorable for an “underperform” pick, but argues that the innate unprofitability of United will show itself eventually:

I'm going to wait this one out. This company is losing $33 a share (Nov. 3, 2008). Just because oil is half price isn’t going to make this company profitable anytime soon if ever.

Shake, rattle, and roll
These stocks have been shaking the market this past month, and it pays to start your own research on them at Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made -- all from a stock's CAPS page.

Follow along with the Global Gains team as they travel to key business centers in China to uncover the very best investing opportunities! Sign up here to receive their FREE dispatches from the road.

Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 28, 2008, at 11:45 AM, bwolfe01 wrote:

    I was a little taken back by this article. It's hard to believe that the thought of, "So here is a company that specializes in tissue derived stem cells supposedly, and has been around for 15 years and is not even profitable", is a sound reason not to invest in STEM. Obviously the author of this article is more of a day trader, and doesn't tend to make long term investments. Just based on the single statement above, that means that: GE, IBM, ADM, ..., were not sound investments because most of these companies went 20 to 30 years without being profitable. I think the real answer here is that most individuals that share the same thought process, are the same individuals looking to make a quick buck as a day trader. Maybe that is why 80% of day traders end up even to down with their investment strategies. If you take a long term approach, factor in the current economy, current age range with the majority of capital, vanity of the "Baby-Boomers", and where they will be spending their retirement. I think you will soon realize that the flow of money will continue to pour into the STEM cell technologies weather the government approves it or not. Also, with the current Govt. in place, and the protectionism afforded Big Pharma by the current administration. The statement that "Only companies engaged in embryonic testing were affected by this policy" is a broad statement that is incorrect. The real question is, how much $$ was invested into STEM cell companies by the federal government, though tax abatements, new research grants, ... The answer is 0$ from the federal Govt. However, states like California, are bypassing the Govt. restrictions and looking to provide funding by the states, for those companies. So to counter states attempting to circumvent the current administrations policies the FDA, which is controlled by the same part of Govt (Executive Branch), that has implemented the policies restricting Govt. funding into STEM technologies. The FDA, in turn has slowed the approval process for clinical trials. Just look at the last 3 months compared to the last 8 years, and compare the clinical trial approval rate (3 to 1 more approvals in the last 3 months). Look at www.opensecrets.org. and the increase Big Pharma donated to the current administration within 60 days after STEM cell ban was put in place. That would be a coincidence in this authors words. Another coincidence that Pfizer would be opening their own research into STEM technologies. Yet another coincidence that Eli Lilly would be jumping into the game.

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 773809, ~/articles/ArticleHandler.aspx, 7/6/2009 1:45:03 AM

Keep Reading:

“10 Stocks to Shake the Market”

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Get involved! »

Most Recent

Jul 2 at 4:22 PM

Market Summary

DJIA 8,280.74 -223.32 -2.63%
S&P 500 896.42 -26.91 -2.91%
NASD 1,796.52 +0.00 +0.00%
Sponsored by:

Related Tickers

Geron Corp

CAPS Rating 2/5 Stars

$7.65

+0.22 (+2.96%)

Outperform507

Underperform78

Rate This Stock